ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 2365

Decoding the Peripheral Immune Landscape of Systemic Sclerosis to Investigate Disease Stages and Interstitial Lung Disease Progression

Vasuki Ranjani Chellamuthu1, Maria Noviani2, Ahmad bin Mohamed Lajam1, Andrea Hsiu Ling Low2 and Salvatore Albani1, 1Translational Immunology Institute, SingHealth, Singapore, Singapore, 2Department of Rheumatology and Immunology, Singapore General Hospital, Singapore, Singapore

Meeting: ACR Convergence 2023

Keywords: Biomarkers, Disease Activity, immunology, interstitial lung disease, Systemic sclerosis

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Tuesday, November 14, 2023

Title: (2352–2369) Systemic Sclerosis & Related Disorders – Clinical Poster III: Translational Science

Session Type: Poster Session C

Session Time: 9:00AM-11:00AM

Background/Purpose: Systemic sclerosis (SSc) is a heterogenous autoimmune disease characterized by fibrosis, vascular abnormalities and immune dysregulation. Characterization of peripheral blood immune signatures in relation to disease stages and progression remains insufficiently defined. Understanding these immune signatures may shed light to SSc pathogenesis underpinning distinct disease stages and states.

Methods: The study included a cohort of SSc patients (n=15), age and sex matched to healthy controls (n=7). We compared immune signatures of SSc patients at different stages (“very early diagnosis of SSc” (VEDOSS), early < 3 years and late >5 years from disease onset) and ILD status (stable vs progressive). Clinical and laboratory parameters were recorded for auto-antibody profile, immunosuppressive treatment and disease activity including ILD status. Peripheral blood mononuclear cells of SSc patients were analysed by high dimensional Mass Cytometry (CyTOF) approach employing 73 unique markers to identify perturbations in SSc immunome in comparison to healthy controls. A high throughput analytical and discovery platform, EPIC (Extended Polydimensional Immune Characterization) was deployed for multi-dimensional data analysis and clustering to identify significantly perturbed immune cell subsets.

Results: Unsupervised clustering revealed significant differences in T and NK cell subsets. Supervised analysis revealed activated CD4+ cells expressing CXCR4 and type 1 IFNs (IFI44 and IFI44L) to be significantly increased in SSc compared to healthy controls. This was particularly more pronounced in the late stage of disease and for patients with stable ILD. CXCR4 are known to mediate migration of lymphocytes, endothelial progenitor cells and stem cells and may play a key role in tissue fibrosis. Conversely, a decreased number of cytotoxic NK cells expressing CX3CR1 were found in SSc. CX3CR1 is a mediator of chemotaxis for immune cells and a significant decrease could potentially indicate impaired immunosurveillance in SSc patients. This subset was significantly decreased in the early and late stages of disease and in stable ILD state.

Conclusion: These findings shed light on the heterogeneity of SSc and provide insights into the differential characteristics of disease stages. Understanding the mechanism underlying SSc disease progression and immune perturbations will aid in early diagnosis and intervention. This could contribute to the development of targeted therapeutic strategies and better management of this debilitating disease. Further investigations are warranted to explore the functional significance of increased activated CD4 cells expressing CXCR4 and decreased cytotoxic NK cells expressing CX3CR1 in SSc, as well as to identify potential therapeutic targets that could mitigate disease progression and restore immune homeostasis in affected individuals.


Disclosures: V. Chellamuthu: None; M. Noviani: None; A. Lajam: None; A. Low: Boehringer-Ingelheim, 6, Janssen, 6; S. Albani: None.

To cite this abstract in AMA style:

Chellamuthu V, Noviani M, Lajam A, Low A, Albani S. Decoding the Peripheral Immune Landscape of Systemic Sclerosis to Investigate Disease Stages and Interstitial Lung Disease Progression [abstract]. Arthritis Rheumatol. 2023; 75 (suppl 9). https://acrabstracts.org/abstract/decoding-the-peripheral-immune-landscape-of-systemic-sclerosis-to-investigate-disease-stages-and-interstitial-lung-disease-progression/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to ACR Convergence 2023

ACR Meeting Abstracts - https://acrabstracts.org/abstract/decoding-the-peripheral-immune-landscape-of-systemic-sclerosis-to-investigate-disease-stages-and-interstitial-lung-disease-progression/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology